Tom Graney, an experienced finance executive, has been promoted to the position of chief executive officer of Oxurion NV from chief financial officer, succeeding Patrik De Haes who will move onto the board of directors as non-executive chairman. Based in Belgium, Oxurion is developing treatments for retinal vascular disorders.
Mr Graney joined Oxurion in October 2020 from Generation Bio Co, a US genetic medicines company where he was CFO. Before that, he was CFO of Vertex Pharmaceuticals Inc. Mr Graney has a master’s degree in business administration from the Leonard N. Stern School of Business at New York University, US.
Oxurion announced the appointment on 17 May 2021.
Copyright 2021 Evernow Publishing Ltd